

AMENDMENT

U.S. Appln. No. 09/428,458

- (A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenylthio)-cAMPS and Rp-piperidino-cAMPS; and
- (B) a pharmaceutically acceptable adjuvant or filler.

Claim 41. The pharmaceutical composition according to Claim 40, wherein said cAMP antagonist is Rp-8-Br-cAMPS.

C' Claim 42. The pharmaceutical composition according to Claim 40, wherein said immunosuppressive disease is selected from the group consisting of AIDS, HIV infection and CVI.

Claim 43. A method of inhibiting the effects mediated by PKA type Ia isozyme comprising administering to subject in need of said inhibition, a pharmaceutical composition comprising:

- SUB D
- (A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenylthio)-cAMPS and Rp-piperidino-cAMPS; and
- (B) a pharmaceutically acceptable adjuvant or filler, so as to inhibit the localization of PKA type Ia isozyme with T cell receptor/CD3 complexes.

Claim 44. The method according to Claim 43, wherein said cAMP antagonist is Rp-8-Br-cAMPS.

AMENDMENT

U.S. Appln. No. 09/428,458

Claim 45. A method of treating a subject afflicted with an immunosuppressive disease, comprising administering to said subject a pharmaceutical composition comprising:

- SUB 2
D
- (A) a pharmaceutically effective amount of a cAMP antagonist; and
 - (B) a pharmaceutically acceptable adjuvant or filler.

Claim 46. The method of Claim 45, wherein said cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type I α isozyme (RI α ₂C₂).

SUB 3
D
C

Claim 47. The method of Claim 46, wherein said cAMP antagonist is a thio-substituted cAMP analog, wherein said thio-substituted cAMP analog is an equatorial diastereomer of 3',5'-cyclic adenosine monophosphorothioate (Rp-cAMPS), and wherein said thio-substituted cAMP analog binds to an RI α subunit of said isozyme and acts as a selective or specific antagonist of said isozyme.

Claim 48. The method of Claim 47, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS, Rp-piperidino-cAMPS, and Rp-8-Cl-cAMPS.

Claim 49. The method of Claim 48, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claim 50. The method of Claim 45, wherein said immunosuppressive disease is selected from the group consisting of AIDS, HIV infection and CVI.